ArticleMedicine2025
Comparison of the prognostic impact of core needle biopsy and intraoperative excisional biopsy in breast cancer: A single-center retrospective cohort study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Core needle biopsy (CNB) and intraoperative excisional biopsy (IEB) are currently the 2 major methods for diagnosing breast cancer in China. The purpose of this study was to compare the prognostic impact of CNB and IEB in breast cancer patients. We retrospectively analyzed breast cancer patients who underwent surgery at the Department of Breast and Thyroid Surgery of the Provincial Hospital Affiliated to Shandong First Medical University between January 2011 and January 2021. Clinicopathological characteristics, disease-free survival (DFS) and overall survival (OS) were compared between the CNB and IEB groups. From January 2011 to January 2021, a total of 2330 newly diagnosed breast cancer patients were enrolled in this retrospective study. The log-rank survival analysis revealed no significant difference in OS between the 2 groups (P = .156), but the CNB group had significantly worse DFS (P = .002). In the subgroup analysis, for the HR+/HER2- subtype, both OS and DFS were significantly lower in the CNB subgroup than in the IEB subgroup. Multivariate survival analyses revealed that CNB was independently associated with shorter DFS (HR: 1.729, 95% CI: 1.228-2.434, P = .002). Among HR+/HER2- patients, CNB was a significant independent risk factor and indicated shorter OS (HR: 1.990, 95% CI: 1.023-3.874, P = .043) and shorter DFS (HR: 2.284, 95% CI: 1.413-3.693, P = .001) than IEB. This study suggests that CNB may be associated with a poorer prognosis in certain breast cancer subtypes, particularly HR+/HER2-, compared to IEB. These findings highlight the need for further clinical investigation to optimize biopsy strategies in breast cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.